Condition
Cerebral Cavernous Malformations
Total Trials
4
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
2Total
Early P 1 (1)
P 2 (1)
Trial Status
Terminated2
Active Not Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT01764529Active Not Recruiting
Modifiers of Disease Severity in Cerebral Cavernous Malformations
NCT03474614Phase 2TerminatedPrimary
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
NCT01764451Early Phase 1Terminated
Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins
NCT03467295UnknownPrimary
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
Showing all 4 trials